Thomas Eschenhagen

Activation of the cardiac endothelin system in left ventricular hypertrophy before onset of heart failure in TG(mREN2)27 rats.

Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension.

Physiological antagonism between ventricular beta 1-adrenoceptors and alpha 1-adrenoceptors but no evidence for beta 2- and beta 3-adrenoceptor function in murine heart.

Specific beta(2)AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta(2)AR in myocytes from failing human heart.

Cardiac ankyrin repeat protein, a negative regulator of cardiac gene expression, is augmented in human heart failure.

Intracellular beta-blockade: overexpression of Galpha(i2) depresses the beta-adrenergic response in intact myocardium.

Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.

Expression of ten RGS proteins in human myocardium: functional characterization of an upregulation of RGS4 in heart failure.

Cardiac tissue engineering.

Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance.

Cardiac grafting of engineered heart tissue in syngenic rats.

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.

3D engineered heart tissue for replacement therapy.

Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes.

Overexpression of wild-type Galpha(i)-2 suppresses beta-adrenergic signaling in cardiac myocytes.

Cardiac tissue engineering for replacement therapy.

Beta-adrenergic stimulation induces cardiac ankyrin repeat protein expression: involvement of protein kinase A and calmodulin-dependent kinase.

Heme oxygenase-1 and its reaction product, carbon monoxide, prevent inflammation-related apoptotic liver damage in mice.

Differential coupling of m-cholinoceptors to Gi/Go-proteins in failing human myocardium.

What is the role of beta-adrenergic signaling in heart failure?

Tissue engineering of aortic heart valves.

Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure.

Engineered heart tissue for regeneration of diseased hearts.

Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts.

Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties.

Formation of molecular complexes by N-methyl-D-aspartate receptor subunit NR2B and ryanodine receptor 2 in neonatal rat myocard.

Effects of chronic endothelin-1 stimulation on cardiac myocyte contractile function.

S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts.

Ouabain treatment is associated with upregulation of phosphatase inhibitor-1 and Na+/Ca(2+)-exchanger and beta-adrenergic sensitization in rat hearts.

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.

Norepinephrine upregulates vascular endothelial growth factor in rat cardiac myocytes by a paracrine mechanism.

Effect of amiodarone on the plasma levels of metoprolol.

Key role of myosin light chain (MLC) kinase-mediated MLC2a phosphorylation in the alpha 1-adrenergic positive inotropic effect in human atrium.

[Beta blockers in cardiac insufficiency. When, how much and which substance].

Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants.

Differential functional effects of two 5-HT4 receptor isoforms in adult cardiomyocytes.

Endothelin-1 and isoprenaline co-stimulation causes contractile failure which is partially reversed by MEK inhibition.

Questioning the relevance of circulating cardiac progenitor cells in cardiac regeneration.

Engineering myocardial tissue.

Alterations of the preproenkephalin system in cardiac hypertrophy and its role in atrioventricular conduction.

Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits.

Electrical coupling of cardiac myocyte cell sheets to the heart.

Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts.

Heart muscle engineering: an update on cardiac muscle replacement therapy.

Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes.

The MLCK-mediated alpha1-adrenergic inotropic effect in atrial myocardium is negatively modulated by PKCepsilon signaling.

Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle.

Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation.

High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.

The 2988G>A polymorphism affects splicing of a CYP2D6 minigene.

Reduced contractile response to alpha1-adrenergic stimulation in atria from mice with chronic cardiac calmodulin kinase II inhibition.

Regulation of cardiac cAMP synthesis and contractility by nucleoside diphosphate kinase B/G protein beta gamma dimer complexes.

Embryonic stem cells for cardiac muscle engineering.

Reproducibility of transthoracic echocardiography in small animals using clinical equipment.

Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure.

Adenovirus-delivered short hairpin RNA targeting PKCalpha improves contractile function in reconstituted heart tissue.

Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes.

Development of a biological ventricular assist device: preliminary data from a small animal model.

Real-time myocardial contrast echocardiography for assessing perfusion and function in healthy and infarcted wistar rats.

Long-term beta-adrenergic stimulation leads to downregulation of protein phosphatase inhibitor-1 in the heart.

Thyroid hormone regulates developmental titin isoform transitions via the phosphatidylinositol-3-kinase/ AKT pathway.

Inhibition of aldehyde dehydrogenase type 2 attenuates vasodilatory action of nitroglycerin in human veins.

ATP-binding cassette transporters in human heart failure.

Beta-adrenergic signaling in heart failure-adapt or die.

The slow force response to stretch in atrial and ventricular myocardium from human heart: functional relevance and subcellular mechanisms.

Angiotensin II and myosin light-chain phosphorylation contribute to the stretch-induced slow force response in human atrial myocardium.

Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial.

Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy.

Unloaded rat hearts in vivo express a hypertrophic phenotype of cardiac repolarization.

Activation of negative regulators of the hypoxia-inducible factor (HIF) pathway in human end-stage heart failure.

Mechanical unloading of the rat heart involves marked changes in the protein kinase-phosphatase balance.

Beta-adrenergic stimulation and myocardial function in the failing heart.

Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects.

Capturing adenylyl cyclases as potential drug targets.

A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy.

Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice.

The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy.

Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction.

Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms.

Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging.

Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation.

[Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].

Development of a drug screening platform based on engineered heart tissue.

Phosphatase-1-inhibitor-1: amplifier or attenuator of catecholaminergic stress?

Myomasp/LRRC39, a heart- and muscle-specific protein, is a novel component of the sarcomeric M-band and is involved in stretch sensing.

Distinction between two populations of islet-1-positive cells in hearts of different murine strains.

The new HNO donor, 1-nitrosocyclohexyl acetate, increases contractile force in normal and β-adrenergically desensitized ventricular myocytes.

Engineering bioartificial tracheal tissue using hybrid fibroblast-mesenchymal stem cell cultures in collagen hydrogels.

Is ryanodine receptor phosphorylation key to the fight or flight response and heart failure?

MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling.

Common microRNA signatures in cardiac hypertrophic and atrophic remodeling induced by changes in hemodynamic load.

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.

Phosphatase-1 inhibitor-1 in physiological and pathological β-adrenoceptor signalling.

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.

Cardiac tissue engineering: a clinical perspective.

The effect of mesenchymal stem cell osteoblastic differentiation on the mechanical properties of engineered bone-like tissue.

Follistatin-like 1 in chronic systolic heart failure: a marker of left ventricular remodeling.

The beat goes on: human heart muscle from pluripotent stem cells.

Terminal differentiation, advanced organotypic maturation, and modeling of hypertrophic growth in engineered heart tissue.

Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology.

Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.

Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy.

Localization of Islet-1-positive cells in the healthy and infarcted adult murine heart.

Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.

Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy.

Complex interactions between human myoblasts and the surrounding 3D fibrin-based matrix.

Physiological aspects of cardiac tissue engineering.

Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: In vivo and in vitro data.

Progesterone receptor variants associated with the PROGINS haplotype exhibit functional properties similar to those of wild-type progesterone receptor.

The German Centre for Cardiovascular Research.

Increased afterload induces pathological cardiac hypertrophy: a new in vitro model.

A novel genetic variant in the transcription factor Islet-1 exerts gain of function on myocyte enhancer factor 2C promoter activity.

Pharmacological characterization of 1-nitrosocyclohexyl acetate, a long-acting nitroxyl donor that shows vasorelaxant and antiaggregatory effects.

New tissue for failing hearts.

A frequent gene polymorphism affecting the heart-rate response to carvedilol.

[Personalized therapy in cardiology. Biomarkers, pharmacogenetics and therapy of monogenic diseases].

Parthenogenetic stem cells for tissue-engineered heart repair.

PDE4 in the human heart - major player or little helper?

Nicotinic acid adenine dinucleotide phosphate (NAADP)-mediated calcium signaling and arrhythmias in the heart evoked by β-adrenergic stimulation.

Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue.

Heterozygous LmnadelK32 mice develop dilated cardiomyopathy through a combined pathomechanism of haploinsufficiency and peptide toxicity.

Development of a colorimetric and a fluorescence phosphatase-inhibitor assay suitable for drug discovery approaches.

Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice.

Phosphodiesterase-2 is Upregulated in Human Failing Hearts and Blunts β-Adrenergic Responses in Cardiomyocytes.

Repair of Mybpc3 mRNA by 5'-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy.

Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.

Functional microRNA library screening identifies the hypoxamir miR-24 as a potent regulator of smooth muscle cell proliferation and vascularization.

Melusin protects from cardiac rupture and improves functional remodelling after myocardial infarction.

In vitro perfusion of engineered heart tissue through endothelialized channels.

Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure.

B-scan ultrasonographic monitoring of orthotopic xenografted plexiform neurofibroma in mice.

[Interview by Anne-Katrin Döbler].

Paradoxical effects on force generation after efficient β1-adrenoceptor knockdown in reconstituted heart tissue.

Cardiac tissue engineering: state of the art.

Automated analysis of contractile force and Ca2+ transients in engineered heart tissue.

Myocardial tissue engineering: in vitro models.

Dichloroacetate prevents restenosis in preclinical animal models of vessel injury.

Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation.

Guanabenz interferes with ER stress and exerts protective effects in cardiac myocytes.

Prostaglandin E2 does not attenuate adrenergic-induced cardiac contractile response.

Generation of strip-format fibrin-based engineered heart tissue (EHT).

Cardiac arrhythmia induced by genetic silencing of 'funny' (f) channels is rescued by GIRK4 inactivation.

The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology.

Effects of proarrhythmic drugs on relaxation time and beating pattern in rat engineered heart tissue.

FHL2 expression and variants in hypertrophic cardiomyopathy.

Development of phosphatase inhibitor-1 peptides acting as indirect activators of phosphatase 1.

Assessment of DNA synthesis in Islet-1⁺ cells in the adult murine heart.

Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice.

Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes.

Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology.

Prolonged action potentials in HCM-derived iPSC--biology or artefact?

LQT1-phenotypes in hiPSC: Are we measuring the right thing?

Immunobiology of fibrin-based engineered heart tissue.

Human engineered heart tissue as a model system for drug testing.

The E3 ubiquitin ligase Asb2β is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation.

Development of Long Noncoding RNA-Based Strategies to Modulate Tissue Vascularization.

β 1 Adrenoceptor antagonistic effects of the supposedly selective β 2 adrenoceptor antagonist ICI 118,551 on the positive inotropic effect of adrenaline in murine hearts.

Pharmacokinetics of the Experimental Non-Nucleosidic DNA Methyl Transferase Inhibitor N-Phthalyl-L-Tryptophan (RG 108) in Rats.

Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy.

General practitioners' adherence to chronic heart failure guidelines regarding medication: the GP-HF study.

Heart regeneration.

Knock-out of nexilin in mice leads to dilated cardiomyopathy and endomyocardial fibroelastosis.

DNA methylation in an engineered heart tissue model of cardiac hypertrophy: common signatures and effects of DNA methylation inhibitors.

Spontaneous Formation of Extensive Vessel-Like Structures in Murine Engineered Heart Tissue.

S-glutathiolation impairs phosphoregulation and function of cardiac myosin-binding protein C in human heart failure.

Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue.

A New Animal Model for Investigation of Mechanical Unloading in Hypertrophic and Failing Hearts: Combination of Transverse Aortic Constriction and Heterotopic Heart Transplantation.

Myocardial tissue engineering for cardiac repair.

Ataxin-10 is part of a cachexokine cocktail triggering cardiac metabolic dysfunction in cancer cachexia.

Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.

Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.

Human Engineered Heart Tissue: Analysis of Contractile Force.

Outcomes of Patients in Long-Term Opioid Maintenance Treatment.

[Not Available].

Block of Na(+)/Ca(2+) exchanger by SEA0400 in human right atrial preparations from patients in sinus rhythm and in atrial fibrillation.

Exogenous Nitric Oxide Protects Human Embryonic Stem Cell-Derived Cardiomyocytes against Ischemia/Reperfusion Injury.

Is Stimulation of Cardiomyocyte Renewal a Facette of Reversible Catecholamine Toxicity?

Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions.

Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells.

Towards a Tissue-Engineered Contractile Fontan-Conduit: The Fate of Cardiac Myocytes in the Subpulmonary Circulation.

Epigallocatechin-3-Gallate Accelerates Relaxation and Ca(2+) Transient Decay and Desensitizes Myofilaments in Healthy and Mybpc3-Targeted Knock-in Cardiomyopathic Mice.

Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.

Thymosin β4 Improves Differentiation and Vascularization of EHTs.

Engineering Cardiac Muscle Tissue: A Maturating Field of Research.

Blinded Contractility Analysis in hiPSC-Cardiomyocytes in Engineered Heart Tissue Format: Comparison With Human Atrial Trabeculae.

Differentiation of cardiomyocytes and generation of human engineered heart tissue.

Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes.

Cardiomyocyte Regeneration: A Consensus Statement.

Human iPSC-derived cardiomyocytes cultured in 3D engineered heart tissue show physiological upstroke velocity and sodium current density.

Prominent differences in left ventricular performance and myocardial properties between right ventricular and left ventricular-based pacing modes in rats.

I-1-deficiency negatively impacts survival in a cardiomyopathy mouse model.

Cardiovascular Research in Germany.

MUSCLEMOTION: A Versatile Open Software Tool to Quantify Cardiomyocyte and Cardiac Muscle Contraction In Vitro and In Vivo.

Low Resting Membrane Potential and Low Inward Rectifier Potassium Currents Are Not Inherent Features of hiPSC-Derived Cardiomyocytes.

Contractile Work Contributes to Maturation of Energy Metabolism in hiPSC-Derived Cardiomyocytes.

[Cardiology 2018 : From basic science to high efficiency medicine].

A new concept of fibroblast dynamics in post-myocardial infarction remodeling.

Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering.

CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy.

Pharmacological inhibition of DNA methylation attenuates pressure overload-induced cardiac hypertrophy in rats.

No effect of thymosin beta-4 on the expression of the transcription factor Islet-1 in the adult murine heart.

Clonal dynamics studied in cultured induced pluripotent stem cells reveal major growth imbalances within a few weeks.

Exaggerated Cardiotoxicity of Sunitinib in Stressed 3-Dimensional Heart Muscles.

From basic science to high performance medicine.

Rat atrial engineered heart tissue: a new in vitro model to study atrial biology.

Satellite cells delivered in their niche efficiently generate functional myotubes in three-dimensional cell culture.

Treatments targeting inotropy.

Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes-a systematic review.

Piezo-bending actuators for isometric or auxotonic contraction analysis of engineered heart tissue.

Normalization of force to muscle cross-sectional area: A helpful attempt to reduce data scattering in contractility studies?

Atrial-like Engineered Heart Tissue: An In Vitro Model of the Human Atrium.

Mechanistic role of the CREB-regulated transcription coactivator 1 in cardiac hypertrophy.

ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure.

Toward Second-Generation Cardiomyogenic and Anti-cardiofibrotic 1,4-Dihydropyridine-Class TGFβ Inhibitors.

Heart Repair With Myocytes.

Dissecting hiPSC-CM pacemaker function in a cardiac organoid model.

Analysis of fibrosis in control or pressure overloaded rat hearts after mechanical unloading by heterotopic heart transplantation.

Human pluripotent stem cell-derived cardiomyocytes for studying energy metabolism.

Human iPS cell-derived engineered heart tissue does not affect ventricular arrhythmias in a guinea pig cryo-injury model.

Author Correction: Differentiation of cardiomyocytes and generation of human engineered heart tissue.

Blockade of miR-140-3p prevents functional deterioration in afterload-enhanced engineered heart tissue.

Unlocking Personalized Biomedicine and Drug Discovery with Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Fit for Purpose or Forever Elusive?

Simultaneous measurement of excitation-contraction coupling parameters identifies mechanisms underlying contractile responses of hiPSC-derived cardiomyocytes.

Chronic intermittent tachypacing by an optogenetic approach induces arrhythmia vulnerability in human engineered heart tissue.

Long Noncoding RNA-Enriched Vesicles Secreted by Hypoxic Cardiomyocytes Drive Cardiac Fibrosis.

A magnetics-based approach for fine-tuning afterload in engineered heart tissues.

Disease modeling of a mutation in α-actinin 2 guides clinical therapy in hypertrophic cardiomyopathy.

Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue.

Force and Calcium Transients Analysis in Human Engineered Heart Tissues Reveals Positive Force-Frequency Relation at Physiological Frequency.

Case Report on: Very Early Afterdepolarizations in HiPSC-Cardiomyocytes-An Artifact by Big Conductance Calcium Activated Potassium Current (I).

Regulation of I and force by PDEs in human-induced pluripotent stem cell-derived cardiomyocytes.

An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations.

Aging-regulated anti-apoptotic long non-coding RNA Sarrah augments recovery from acute myocardial infarction.

Toward standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function.